Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

The Lancet Oncology - Tập 16 Số 8 - Trang 928-936 - 2015
Amit M. Oza1, Adrian Cook2, Jacobus Pfisterer3, Andrew Embleton-Thirsk2, Jonathan A. Ledermann4, Éric Pujade-Lauraine5, Gunnar B. Kristensen6, Mark S. Carey7, Philip Beale8, Andrés Cervantes9, Tjoung‐Won Park‐Simon10, Gordon Rustin11, Florence Joly12, Mansoor Raza Mirza13, Marie Plante14, Michael Quinn15, Andrés Poveda16, Gordon C. Jayson17, Dan Stark18, Ann Marie Swart19, Laura Farrelly2, Richard Kaplan2, Mahesh Parmar2, Timothy Perren18
1Princess Margaret Cancer Centre, Toronto, ON, Canada
2Medical Research Council Clinical Trials Unit at University College London, London, UK
3Gynecologic Oncology Center, AGO Study Group, Kiel, Germany
4Cancer Clinical Trials Unit, University College London Hospital, London, UK
5AP-HP, Site Hôtel-Dieu, Université Paris Descartes, Paris, France
6Department of Gynaecologic Oncology and Institute for Cancer Genetics and Informatics, Oslo University Hospital, Institute for Clinical Medicine, Oslo University, Norway.
7University of British Columbia, Vancouver, Canada
8Concord Hospital, Sydney, NSW, Australia
9Department of Haematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain
10Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany
11Mount Vernon Hospital, London, UK
12Centre François Baclesse Caen, France
13Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark
14Centre Hospitalier Universitaire de Québec, L'Hôtel-Dieu de Québec, Canada
15Royal Women’s Hospital, Melbourne, Australia
16Fundación Instituto Valenciano de Oncología, Valencia, Spain
17Institute of Cancer Sciences and Christie Hospital, University of Manchester, Manchester, UK
18St James’ Institute of Oncology, St James’ University Hospital, Leeds, UK
19Norwich Clinical Trials Unit, University of East Anglia, Norwich, UK

Tóm tắt

Từ khóa


Tài liệu tham khảo

De Angelis, 2014, Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study, Lancet Oncol, 15, 23, 10.1016/S1470-2045(13)70546-1

Stuart, 2011, 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference, Int J Gynecol Cancer, 21, 750, 10.1097/IGC.0b013e31821b2568

Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108

Burger, 2011, Incorporation of bevacizumab in the primary treatment of ovarian cancer, N Engl J Med, 365, 2473, 10.1056/NEJMoa1104390

Perren, 2011, A Phase 3 trial of bevacizumab in ovarian cancer, N Engl J Med, 365, 2484, 10.1056/NEJMoa1103799

Aghajanian, 2012, OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer, J Clin Oncol, 30, 2039, 10.1200/JCO.2012.42.0505

Pujade-Lauraine, 2014, Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial, J Clin Oncol, 32, 1302, 10.1200/JCO.2013.51.4489

Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205

Royston, 2002, Flexible poportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects, Stat Med, 21, 2175, 10.1002/sim.1203

Witteveen, 2013, Late breaking abstract: final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC), Eur J Cancer, 49, S3

Coleman, 2015, Gynecol Oncol, 137, 3, 10.1016/j.ygyno.2015.01.005

Bennouna, 2013, Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial, Lancet Oncol, 14, 29, 10.1016/S1470-2045(12)70477-1

von Minckwitz, 2014, Lancet Oncol, 15, 1269, 10.1016/S1470-2045(14)70439-5

Katsumata, 2009, Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial, Lancet, 374, 1331, 10.1016/S0140-6736(09)61157-0

Chan, 2013, Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262, Int J Gynecol Cancer, 23, 9

Stark, 2013, Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial, Lancet Oncol, 14, 236, 10.1016/S1470-2045(12)70567-3

Collinson, 2013, Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection, Clin Cancer Res, 19, 5227, 10.1158/1078-0432.CCR-13-0489

Backen, 2014, The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer, Clin Cancer Res, 20, 4549, 10.1158/1078-0432.CCR-13-3248

Gourley, 2014, Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab, Proc Am Soc Clin Oncol, 32

Winterhoff, 2014, Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer, Proc Am Soc Clin Oncol, 32

Thông tin
Thông tin xuất bản

The Lancet Oncology

Tập 16 Số 8

928-936

Thông tin tác giả